A new malaria vaccine delivered through easy-to-use microneedle patches
Official title: Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches
Funded at L2 Diagnostics, LLC · NIH-11095978 · Data updated 2026-11-12
This study is working on a new malaria vaccine that uses a protein from mosquito saliva and is delivered through easy-to-use microneedle patches, making it less painful and more convenient, especially for people in areas with limited resources.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | L2 Diagnostics, LLC NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $299,862 |
| NIH project number | 5R41AI184218-02 |
| Project ID | NIH-11095978 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals living in malaria-endemic regions who are at risk of malaria infection.
✕Less likely to help
Patients who do not live in malaria-endemic areas or those who are not at risk for malaria may not benefit from this research.
What this research studies
This research focuses on developing a malaria vaccine using a protein from the saliva of Anopheles gambiae mosquitoes, delivered via innovative microneedle patches. These patches are designed to be self-applied, minimizing pain and waste compared to traditional injections. The project aims to create a vaccine that can be stored at room temperature for up to six months, making it suitable for use in resource-limited settings. The ultimate goal is to prepare this vaccine for future clinical trials in humans after successful testing in mice.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective and easily administered malaria vaccine, significantly reducing malaria infections in vulnerable populations.
How similar studies have gone: Other research has shown promise in developing vaccines using similar delivery methods, but this specific approach with AgTRIOVx is novel.
Where this research is happening
-
L2 Diagnostics, LLC
New Haven, United States Active
Researchers
- Principal investigator: Anthony, Karen G. — L2 Diagnostics, LLC
- Study coordinator: Anthony, Karen G.
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.